Sara Llufriu

List of Publications by Year
in descending order

89 papers	3,933 citations	147801 31 h-index	133252 59 g-index
96 all docs	96 docs citations	96 times ranked	6081 citing authors

#	Article	IF	Citations
1	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurology, The, 2018, 17, 760-772.	10.2	422
2	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
3	Autoimmune postâ€"herpes simplex encephalitis of adults and teenagers. Neurology, 2015, 85, 1736-1743.	1.1	226
4	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. Annals of Neurology, 2014, 75, 98-107.	5.3	206
5	Plasma exchange for acute attacks of CNS demyelination. Neurology, 2009, 73, 949-953.	1.1	174
6	Dynamics of retinal injury after acute optic neuritis. Annals of Neurology, 2015, 77, 517-528.	5.3	142
7	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	4.2	135
8	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS ONE, 2014, 9, e113936.	2.5	131
9	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.8	122
10	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
11	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	7.2	115
12	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	7.1	112
13	Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study. Journal of Neuroimmunology, 2009, 215, 31-35.	2.3	91
14	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
15	Structural networks involved in attention and executive functions in multiple sclerosis. NeuroImage: Clinical, 2017, 13, 288-296.	2.7	87
16	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	3.0	77
17	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. PLoS ONE, 2012, 7, e37167.	2.5	68
18	Generic acquisition protocol for quantitative MRI of the spinal cord. Nature Protocols, 2021, 16, 4611-4632.	12.0	65

#	Article	IF	Citations
19	Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. JAMA Neurology, 2014, 71, 840.	9.0	57
20	Rapidly progressive diffuse Lewy body disease. Movement Disorders, 2011, 26, 1316-1323.	3.9	56
21	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
22	Cognitive functions in multiple sclerosis: impact of gray matter integrity. Multiple Sclerosis Journal, 2014, 20, 424-432.	3.0	47
23	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	3.6	47
24	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	44
25	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2016, 9, 436-440.	3.5	43
26	Improved Framework for Tractography Reconstruction of the Optic Radiation. PLoS ONE, 2015, 10, e0137064.	2.5	39
27	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
28	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	3.0	36
29	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	3.0	35
30	Colour vision impairment is associated with disease severity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1207-1216.	3.0	35
31	Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. Journal of Neurology, 2015, 262, 2491-2497.	3.6	35
32	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	9.0	32
33	Diffusion-Weighted Imaging: Recent Advances and Applications. Seminars in Ultrasound, CT and MRI, 2021, 42, 490-506.	1.5	30
34	Time efficient whole-brain coverage with MR Fingerprinting using slice-interleaved echo-planar-imaging. Scientific Reports, 2018, 8, 6667.	3.3	29
35	Incidence and Impact of COVID-19 in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	29
36	Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers. Scientific Data, 2021, 8, 219.	5.3	27

#	Article	IF	Citations
37	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Research Notes, 2014, 7, 910.	1.4	26
38	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. Multiple Sclerosis and Related Disorders, 2020, 38, 101483.	2.0	23
39	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	6.5	23
40	Retrograde retinal damage after acute optic tract lesion in MS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 824-826.	1.9	22
41	Walking function in clinical monitoring of multiple sclerosis by telemedicine. Journal of Neurology, 2015, 262, 1706-1713.	3.6	22
42	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	2.7	22
43	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	2.3	21
44	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	2.5	21
45	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. NeuroImage: Clinical, 2021, 30, 102653.	2.7	21
46	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	3.3	20
47	Longitudinal Retinal Changes in <scp>MOGAD</scp>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
48	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	2.0	18
49	Defective sensorimotor integration in preparation for reaction time tasks in patients with multiple sclerosis. Journal of Neurophysiology, 2015, 113, 1462-1469.	1.8	17
50	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 333-339.	2.0	17
51	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. Multiple Sclerosis Journal, 2019, 25, 801-810.	3.0	17
52	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	9.0	17
53	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. Scientific Reports, 2021, 11, 16805.	3.3	17
54	T2 hypointense rims and ring-enhancing lesions in MS. Multiple Sclerosis Journal, 2010, 16, 1317-1325.	3.0	16

#	Article	IF	Citations
55	CSF Chitinase 3â€"Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
56	Abnormal Control of Orbicularis Oculi Reflex Excitability in Multiple Sclerosis. PLoS ONE, 2014, 9, e103897.	2.5	14
57	Visual field impairment captures disease burden in multiple sclerosis. Journal of Neurology, 2016, 263, 695-702.	3.6	14
58	Accelerated white matter lesion analysis based on simultaneous T₁ and T₂^{â^—} quantification using magnetic resonance fingerprinting and deep learning. Magnetic Resonance in Medicine, 2021, 86, 471-486.	3.0	12
59	Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. NeuroImage: Clinical, 2020, 28, 102411.	2.7	11
60	A NOTCH3 homozygous nonsense mutation in familial Sneddon syndrome with pediatric stroke. Journal of Neurology, 2021, 268, 810-816.	3.6	11
61	Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value. Scientific Reports, 2019, 9, 20172.	3.3	10
62	Applying multilayer analysis to morphological, structural, and functional brain networks to identify relevant dysfunction patterns. Network Neuroscience, 2022, 6, 916-933.	2.6	10
63	Familial Sneddon's syndrome with microbleeds in MRI. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 962-962.	1.9	9
64	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. Therapeutic Advances in Neurological Disorders, 2017, 10, 367-372.	3.5	9
65	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. Journal of the Neurological Sciences, 2015, 359, 146-150.	0.6	8
66	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. Multiple Sclerosis Journal, 2017, 23, 1762-1771.	3.0	8
67	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 581700.	2.4	8
68	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	3.0	8
69	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1107.	2.5	8
70	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	3.5	7
71	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis. , 2021, 62, 11.		7
72	A Prospective Cohort of SARS-CoV-2-Infected Health Care Workers: Clinical Characteristics, Outcomes, and Follow-up Strategy. Open Forum Infectious Diseases, 2021, 8, ofaa592.	0.9	7

#	Article	IF	Citations
73	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. Journal of the Neurological Sciences, 2015, 352, 127-128.	0.6	6
74	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. Journal of Personalized Medicine, 2022, 12, 743.	2.5	6
75	Enhanced mirror activity in â€˜crossedâ€™ reaction time tasks in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2001-2009.	1.5	5
76	Taking care of kidney transplant recipients during the COVIDâ€19 pandemic: Experience from a medicalized hotel. Clinical Transplantation, 2021, 35, e14132.	1.6	5
77	Fully automated delineation of the optic radiation for surgical planning using clinically feasible sequences. Human Brain Mapping, 2021, 42, 5911-5926.	3.6	5
78	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. Journal of Neurology, 2015, 262, 219-221.	3.6	3
79	Lesion probability mapping in MS patients using a regression network on MR fingerprinting. BMC Medical Imaging, 2021, 21, 107.	2.7	3
80	Changes in Your Breathing Can Change Your Brain. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 763-764.	5.6	2
81	Familial Sneddon's syndrome with microbleeds in MRI. BMJ Case Reports, 2009, 2009, bcr2007131912-bcr2007131912.	0.5	2
82	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. Neuroradiology, 2022, 64, 1383-1390.	2.2	2
83	Longitudinally extensive myelitis in a patient with characteristic autoantibody profile of systemic lupus erythematosus: a challenging etiological diagnosis. Lupus, 2014, 23, 1555-1556.	1.6	1
84	Vanishing spinal cord after varicella-zoster virus myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e364.	6.0	1
85	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	2.5	1
86	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	4.8	1
87	Reply: Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2585-2585.	3.9	0
88	White and Gray Matter Impairment in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 207-208.	5.6	0
89	Abstract 15640: Long Term Moderate, but Not Intense, Exercise Improves Cognitive Brain Health. Study in a Rat Model. Circulation, 2020, 142, .	1.6	0